Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano Malattie EMatologiche dell'Adulto
Explore linked clinical trials.40 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute promyelocytic leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Not applicable | 2026-10-09 | NCT07867704 | |
| Real World Assessment of Venous Thromboembolic Risk in Hospitalized Patients With Acute Leukemia | acute leukemia | Not yet recruiting | Not stated | 2026-09-21 | NCT07831668 | |
| IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, disease, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-08-14 | NCT06713837 | |
| Master Framework For Relapse or Refractory Acute Myeloid Leukemia | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not stated | 2026-08-14 | NCT06459024 | |
| Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-07-16 | NCT03610438 | |
| Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not stated | 2026-06-22 | NCT07080970 | |
| Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Not stated | 2026-06-11 | NCT07640750 | |
| Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Not stated | 2026-06-09 | NCT04282811 | |
| CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Not yet recruiting | Not stated | 2026-06-03 | NCT07623655 | |
| Infection Surveillance of R/R Multiple Myeloma Patients Treated With Elranatamab as Clinical Practice in Italy | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Not stated | 2026-05-04 | NCT07564128 | |
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-04-30 | NCT04608318 | |
| Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-03-17 | NCT05478512 | |
| Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-03-06 | NCT05306301 | |
| Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Not applicable | 2026-03-06 | NCT04460963 | |
| Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-03-05 | NCT06253637 | |
| Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Not stated | 2026-01-21 | NCT07356960 | |
| Momelotinib Effectiveness in Myelofibrosis | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Not yet recruiting | Not stated | 2025-11-25 | NCT07249606 | |
| Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY). | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, myeloproliferative neoplasm | Active, not recruiting | Not stated | 2025-09-23 | NCT04378855 | |
| Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2025-09-10 | NCT06933277 | |
| Identification of BCR::ABL1 Mutations by Digital PCR in CML | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Not applicable | 2025-09-05 | NCT07158294 | |
| Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2025-08-19 | NCT07075016 | |
| Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not stated | 2025-08-13 | NCT06513273 | |
| HRQoL and Financial Toxicity in Patients With VEXAS Syndrome | VEXAS syndrome | Recruiting | Not stated | 2025-07-15 | NCT06657846 | |
| PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2025-07-08 | NCT06409936 | |
| Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Not stated | 2025-06-12 | NCT03190525 |